Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Linn

Showing results (321-330 of 430) with videos related to

Pageof 43
Sort By:
JAMA|April 2, 2024
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerRoberto A Leon-Ferre, Sarah Flora Jonas, Roberto Salgado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell MicroenvironmentsLennart Kester, Danielle Seinstra, Annelot G J van Rossum, et al.
NPJ Breast Cancer|September 9, 2023
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trialSonja Vliek, Florentine S Hilbers, Erik van Werkhoven, et al.
Nature Medicine|May 16, 2019
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trialLeonie Voorwerk, Maarten Slagter, Hugo M Horlings, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2022
Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic TherapyVincent M T de Jong, Yuwei Wang, Natalie D Ter Hoeve, et al.
Nature Medicine|June 19, 2019
Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trialLeonie Voorwerk, Maarten Slagter, Hugo M Horlings, et al.
Cancer|May 16, 2024
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort studyFrancesco Schettini, Eva Blondeaux, Chiara Molinelli, et al.
Nature Medicine|September 16, 2024
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trialIris Nederlof, Olga I Isaeva, Manon de Graaf, et al.
Scientific Reports|January 6, 2016
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancerMagali Michaut, Suet-Feung Chin, Ian Majewski, et al.
The Journal of Trauma and Acute Care Surgery|October 23, 2021
Prehospital end-tidal carbon dioxide is predictive of death and massive transfusion in injured patients: An Eastern Association for Surgery of Trauma multicenter trialEric M Campion, Alexis Cralley, Angela Sauaia, et al.
Pageof 43

Showing results (321-330 of 430) with videos related to

Sort By:
Pageof 43
JAMA|April 2, 2024
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerRoberto A Leon-Ferre, Sarah Flora Jonas, Roberto Salgado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell MicroenvironmentsLennart Kester, Danielle Seinstra, Annelot G J van Rossum, et al.
NPJ Breast Cancer|September 9, 2023
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trialSonja Vliek, Florentine S Hilbers, Erik van Werkhoven, et al.
Nature Medicine|May 16, 2019
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trialLeonie Voorwerk, Maarten Slagter, Hugo M Horlings, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2022
Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic TherapyVincent M T de Jong, Yuwei Wang, Natalie D Ter Hoeve, et al.
Nature Medicine|June 19, 2019
Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trialLeonie Voorwerk, Maarten Slagter, Hugo M Horlings, et al.
Cancer|May 16, 2024
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort studyFrancesco Schettini, Eva Blondeaux, Chiara Molinelli, et al.
Nature Medicine|September 16, 2024
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trialIris Nederlof, Olga I Isaeva, Manon de Graaf, et al.
Scientific Reports|January 6, 2016
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancerMagali Michaut, Suet-Feung Chin, Ian Majewski, et al.
The Journal of Trauma and Acute Care Surgery|October 23, 2021
Prehospital end-tidal carbon dioxide is predictive of death and massive transfusion in injured patients: An Eastern Association for Surgery of Trauma multicenter trialEric M Campion, Alexis Cralley, Angela Sauaia, et al.
Pageof 43